Your session is about to expire
← Back to Search
Behavioral Intervention
Precision Care for Depression
Phase 4
Waitlist Available
Led By Andrew D. Krystal, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
English speaker
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 weeks after randomization.
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved
No Placebo-Only Group
Summary
This trial will evaluate if using a personalized approach to select treatments based on individual characteristics is better than the current method of clinicians and patients deciding on treatments for depression without personalized guidance.
Who is the study for?
This trial is for individuals with major depressive disorder who are seeking new treatment options. Participants should be diagnosed with depression and willing to try different therapies such as mindfulness, medication, or standard care.
What is being tested?
The study tests if choosing treatments based on individual characteristics (phenotyping) is better than usual selection methods for depression. Therapies include Mindfulness-based Stress Sensitivity Therapy, medications like Pramipexole and Phenelzine, and standard care.
What are the potential side effects?
Possible side effects may include nausea, dizziness from Pramipexole; insomnia or increased blood pressure from Methylphenidate; headaches or sleepiness from Phenelzine; and general discomfort from therapy sessions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I speak English.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 weeks after randomization.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 weeks after randomization.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) score
Secondary study objectives
Clinically Useful Depression Outcome Scale Anxious Distress Specifier Subscale (CUDOS-A) score
Generalized Anxiety Disorder 7-item (GAD-7) score
Inventory of Complicated Grief (ICG) score
+6 moreAwards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
10Treatment groups
Experimental Treatment
Active Control
Group I: Stress sensitivity: PSIExperimental Treatment1 Intervention
Group II: Grief: PSIExperimental Treatment1 Intervention
Group III: Cognitive deficits: PSIExperimental Treatment1 Intervention
Group IV: Anxious distress: PSIExperimental Treatment1 Intervention
Group V: Anhedonia phenotype: PSIExperimental Treatment1 Intervention
Group VI: Anhedonia phenotype: CAUActive Control1 Intervention
Group VII: Anxious distress: CAUActive Control1 Intervention
Group VIII: Stress sensitivity: CAUActive Control1 Intervention
Group IX: Grief: CAUActive Control1 Intervention
Group X: Cognitive deficits: CAUActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pramipexole
2008
Completed Phase 4
~11170
Methylphenidate
2014
Completed Phase 4
~431850
Phenelzine
2021
Completed Phase 1
~220
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,800 Total Patients Enrolled
Andrew D. Krystal, MDPrincipal InvestigatorUniversity of California, San Francisco